134 related articles for article (PubMed ID: 18247384)
1. Discovery of new hexagonal supramolecular nanostructures formed by squalenoylation of an anticancer nucleoside analogue.
Couvreur P; Reddy LH; Mangenot S; Poupaert JH; Desmaële D; Lepêtre-Mouelhi S; Pili B; Bourgaux C; Amenitsch H; Ollivon M
Small; 2008 Feb; 4(2):247-53. PubMed ID: 18247384
[TBL] [Abstract][Full Text] [Related]
2. Anticancer efficacy of squalenoyl gemcitabine nanomedicine on 60 human tumor cell panel and on experimental tumor.
Reddy LH; Renoir JM; Marsaud V; Lepetre-Mouelhi S; Desmaële D; Couvreur P
Mol Pharm; 2009; 6(5):1526-35. PubMed ID: 19634915
[TBL] [Abstract][Full Text] [Related]
3. Preclinical toxicology (subacute and acute) and efficacy of a new squalenoyl gemcitabine anticancer nanomedicine.
Reddy LH; Marque PE; Dubernet C; Mouelhi SL; Desmaële D; Couvreur P
J Pharmacol Exp Ther; 2008 May; 325(2):484-90. PubMed ID: 18258784
[TBL] [Abstract][Full Text] [Related]
4. ["Squalenoylation": a new approach to the design of anticancer and antiviral nanomedicines].
Couvreur P
Bull Acad Natl Med; 2009 Mar; 193(3):663-73; discussion 673-4. PubMed ID: 19883017
[TBL] [Abstract][Full Text] [Related]
5. Interaction of a new anticancer prodrug, gemcitabine-squalene, with a model membrane: coupled DSC and XRD study.
Pili B; Bourgaux C; Amenitsch H; Keller G; Lepêtre-Mouelhi S; Desmaële D; Couvreur P; Ollivon M
Biochim Biophys Acta; 2010 Aug; 1798(8):1522-32. PubMed ID: 20435013
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic modalities of squalenoyl nanocomposites in colon cancer: an ongoing search for improved efficacy.
Maksimenko A; Alami M; Zouhiri F; Brion JD; Pruvost A; Mougin J; Hamze A; Boissenot T; Provot O; Desmaële D; Couvreur P
ACS Nano; 2014 Mar; 8(3):2018-32. PubMed ID: 24555414
[TBL] [Abstract][Full Text] [Related]
7. Squalenoylation: a generic platform for nanoparticular drug delivery.
Desmaële D; Gref R; Couvreur P
J Control Release; 2012 Jul; 161(2):609-18. PubMed ID: 21840355
[TBL] [Abstract][Full Text] [Related]
8. Liposomal squalenoyl-gemcitabine: formulation, characterization and anticancer activity evaluation.
Pili B; Reddy LH; Bourgaux C; Lepêtre-Mouelhi S; Desmaële D; Couvreur P
Nanoscale; 2010 Aug; 2(8):1521-6. PubMed ID: 20820745
[TBL] [Abstract][Full Text] [Related]
9. Interaction of self-assembled squalenoyl gemcitabine nanoparticles with phospholipid-cholesterol monolayers mimicking a biomembrane.
Ambike A; Rosilio V; Stella B; Lepêtre-Mouelhi S; Couvreur P
Langmuir; 2011 Apr; 27(8):4891-9. PubMed ID: 21413743
[TBL] [Abstract][Full Text] [Related]
10. Magnetoresponsive squalenoyl gemcitabine composite nanoparticles for cancer active targeting.
Arias JL; Reddy LH; Couvreur P
Langmuir; 2008 Jul; 24(14):7512-9. PubMed ID: 18540685
[TBL] [Abstract][Full Text] [Related]
11. Interfacial behavior of PEGylated lipids and their effect on the stability of squalenoyl-drug nanoassemblies.
Bekkara-Aounallah F; Ambike A; Gref R; Couvreur P; Rosilio V
Int J Pharm; 2014 Aug; 471(1-2):75-82. PubMed ID: 24811925
[TBL] [Abstract][Full Text] [Related]
12. A unique multidrug nanomedicine made of squalenoyl-gemcitabine and alkyl-lysophospholipid edelfosine.
Rodríguez-Nogales C; Sebastián V; Irusta S; Desmaële D; Couvreur P; Blanco-Prieto MJ
Eur J Pharm Biopharm; 2019 Nov; 144():165-173. PubMed ID: 31546021
[TBL] [Abstract][Full Text] [Related]
13. Squalene based nanocomposites: a new platform for the design of multifunctional pharmaceutical theragnostics.
Arias JL; Reddy LH; Othman M; Gillet B; Desmaële D; Zouhiri F; Dosio F; Gref R; Couvreur P
ACS Nano; 2011 Feb; 5(2):1513-21. PubMed ID: 21275408
[TBL] [Abstract][Full Text] [Related]
14. Squalenoyl nanomedicines as potential therapeutics.
Couvreur P; Stella B; Reddy LH; Hillaireau H; Dubernet C; Desmaële D; Lepêtre-Mouelhi S; Rocco F; Dereuddre-Bosquet N; Clayette P; Rosilio V; Marsaud V; Renoir JM; Cattel L
Nano Lett; 2006 Nov; 6(11):2544-8. PubMed ID: 17090088
[TBL] [Abstract][Full Text] [Related]
15. A new nanomedicine of gemcitabine displays enhanced anticancer activity in sensitive and resistant leukemia types.
Reddy LH; Dubernet C; Mouelhi SL; Marque PE; Desmaele D; Couvreur P
J Control Release; 2007 Dec; 124(1-2):20-7. PubMed ID: 17878060
[TBL] [Abstract][Full Text] [Related]
16. Self-assembled drug delivery systems. Part 8: In vitro/in vivo studies of the nanoassemblies of cholesteryl-phosphonyl gemcitabine.
Li M; Qi S; Jin Y; Dong J
Int J Pharm; 2015 Jan; 478(1):124-130. PubMed ID: 25448574
[TBL] [Abstract][Full Text] [Related]
17. Squalenoyl gemcitabine nanomedicine overcomes the low efficacy of gemcitabine therapy in pancreatic cancer.
Réjiba S; Reddy LH; Bigand C; Parmentier C; Couvreur P; Hajri A
Nanomedicine; 2011 Dec; 7(6):841-9. PubMed ID: 21419876
[TBL] [Abstract][Full Text] [Related]
18. Self-assembly of polyisoprenoyl gemcitabine conjugates: influence of supramolecular organization on their biological activity.
Lepeltier E; Bourgaux C; Maksimenko A; Meneau F; Rosilio V; Sliwinski E; Zouhiri F; Desmaële D; Couvreur P
Langmuir; 2014 Jun; 30(22):6348-57. PubMed ID: 24835925
[TBL] [Abstract][Full Text] [Related]
19. Squalenoylation favorably modifies the in vivo pharmacokinetics and biodistribution of gemcitabine in mice.
Reddy LH; Khoury H; Paci A; Deroussent A; Ferreira H; Dubernet C; Declèves X; Besnard M; Chacun H; Lepêtre-Mouelhi S; Desmaële D; Rousseau B; Laugier C; Cintrat JC; Vassal G; Couvreur P
Drug Metab Dispos; 2008 Aug; 36(8):1570-7. PubMed ID: 18474674
[TBL] [Abstract][Full Text] [Related]
20. Gemcitabine and γ-cyclodextrin/docetaxel inclusion complex-loaded liposome for highly effective combinational therapy of osteosarcoma.
Sun L; Zhou DS; Zhang P; Li QH; Liu P
Int J Pharm; 2015 Jan; 478(1):308-317. PubMed ID: 25433201
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
